Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004579
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
Sponsor:
Walter Reed Army Institute of Research WRAIR
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Dose-Ranging Trial of the Pasteur Merieux Connaught PMC Oligomeric HIV-1 gp160MNLAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV vCP205 in HIV Seronegative Adults
Status:
COMPLETED
Status Verified Date:
2003-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see whether an HIV vaccine ALVAC vCP205 is safe and can prevent HIV infection The vCP205 vaccine will be tested with another vaccine gp160MNLAI-2
Detailed Description:
This study consists of 2 parts
Part A Dose-escalation protocol using oligomeric gp160MNLAI-2 Part B Placebo-controlled randomized double-blind within arm study of vCP205 priming with gp160MNLAI-2 boosting
Volunteers are followed for at least 1 year
Part A Dose-escalation protocol using oligomeric gp160MNLAI-2 Part B Placebo-controlled randomized double-blind within arm study of vCP205 priming with gp160MNLAI-2 boosting
Volunteers are followed for at least 1 year
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: